- Home
- LLY vs NVO Comparison
LLY vs NVO Comparison
Compare LLY & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LLY
- NVO
- Stock Information
- Founded
- LLY 1876
- NVO 1923
- Country
- LLY United States
- NVO Denmark
- Employees
- LLY N/A
- NVO N/A
- Industry
- LLY Biotechnology: Pharmaceutical Preparations
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LLY Health Care
- NVO Health Care
- Exchange
- LLY Nasdaq
- NVO Nasdaq
- Market Cap
- LLY 652.7B
- NVO 530.0B
- IPO Year
- LLY N/A
- NVO N/A
- Fundamental
- Price
- LLY $839.96
- NVO $58.08
- Analyst Decision
- LLY Strong Buy
- NVO Strong Buy
- Analyst Count
- LLY 17
- NVO 4
- Target Price
- LLY $1,020.35
- NVO $128.00
- AVG Volume (30 Days)
- LLY 4.0M
- NVO 9.7M
- Earning Date
- LLY 05-01-2025
- NVO 05-07-2025
- Dividend Yield
- LLY 0.71%
- NVO 2.77%
- EPS Growth
- LLY 101.90
- NVO 21.54
- EPS
- LLY 11.71
- NVO 3.14
- Revenue
- LLY $45,042,700,000.00
- NVO $40,314,376,667.00
- Revenue This Year
- LLY $33.50
- NVO $22.57
- Revenue Next Year
- LLY $19.40
- NVO $17.01
- P/E Ratio
- LLY $71.73
- NVO $20.29
- Revenue Growth
- LLY 32.00
- NVO 25.03
- 52 Week Low
- LLY $677.09
- NVO $57.28
- 52 Week High
- LLY $972.53
- NVO $148.15
- Technical
- Relative Strength Index (RSI)
- LLY 57.93
- NVO 30.22
- Support Level
- LLY $730.34
- NVO $59.32
- Resistance Level
- LLY $765.31
- NVO $66.75
- Average True Range (ATR)
- LLY 36.74
- NVO 2.77
- MACD
- LLY 4.69
- NVO -0.05
- Stochastic Oscillator
- LLY 90.03
- NVO 6.29
About LLY Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
About NVO Novo Nordisk A/S
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.